Scarica l'app Stockscreener
1.29
1.57%
0.02
Dopo l'orario di chiusura:
1.28
-0.01
-0.78%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché OPK Giù?
Forum
Previsione
Opko Health Inc Borsa (OPK) Ultime notizie
Here's why you should retain OPK stock in your portfolio for now - MSN
Here's Why You Should Retain OPK Stock in Your Portfolio for Now - Zacks Investment Research
OPKO Health stock (US68375N1037): earnings update keeps focus on pipeline and Rayaldee outlook - AD HOC NEWS
OPKO Health (OPK) price target increased by 11.18% to 3.86 - MSN
OPKO Health stock (US68375N1037): Company updates keep the biotech name in focus - AD HOC NEWS
Opko Health, Inc.Common Stock (NQ: OPK - FinancialContent
OPKO Health stock (US68375N1037): Genomics leader with recent subsidiary activity - AD HOC NEWS
ModeX to present preclinical CAR-T data at gene therapy meeting - Investing.com UK
OPKO Health’s ModeX Therapeutics Will Present Data - GlobeNewswire
Spotlight On Promising Penny Stocks For May 2026 - simplywall.st
OPK.O| Stock Price & Latest News - Reuters
Here's why you should hold OPK stock in your portfolio for now - msn.com
OPKO Health, Inc. (NASDAQ:OPK) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
MSN Money - MSN
OPK Stock Price, Quote & Chart | OPKO HEALTH INC (NASDAQ:OPK) - ChartMill
OPKO Health, Inc. (NASDAQ:OPK) Just Reported And Analysts Have Been Lifting Their Price Targets - 富途牛牛
HC Wainwright Boosts Earnings Estimates for OPKO Health - MarketBeat
OPKO Health : Notice Annual Meeting of stockholders be held on Thursday, June 18, 2026. - marketscreener.com
OPKO gains 15% stake in Nicoya for China RAYALDEE rights - Investing.com UK
[ARS] OPKO HEALTH, INC. SEC Filing - Stock Titan
Board structure and pay detailed in OPKO Health (NASDAQ: OPK) 2026 proxy - Stock Titan
OPKO gains 15% stake in Nicoya for China RAYALDEE rights By Investing.com - Investing.com South Africa
OPKO Health receives 15% stake in Nicoya for China drug rights - StreetInsider
OPKO Health Expands Nicoya Agreement to Support RAYALDEE® Commercialization in Greater China - marketscreener.com
Q1 Earnings Estimate for OPKO Health Issued By HC Wainwright - MarketBeat
Order lab tests online or at home: BioReference opens new platform - Stock Titan
BioReference Launches BioReference Direct, Expanding Access to Consumer-Initiated Diagnostic Testing Through a Fully Integrated Digital Platform - Moomoo
OPKO Health (OPK) reports Q1 loss, misses revenue estimates - MSN
OPKO Health Q1 Earnings In-Line on Product Gains, Revenues Down Y/Y - sharewise.com
OPKO Health Down Over 13%, On Pace for Largest Percent Decrease Since January 2024 -- Data Talk - Moomoo
OPKO Health (NASDAQ:OPK) Hits New 1-Year LowShould You Sell? - MarketBeat
This Purple Innovation Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - Benzinga
H.C. Wainwright reiterates Opko Health stock rating on Q1 results By Investing.com - Investing.com Australia
OPKO Health (NASDAQ:OPK) Downgraded to "Market Perform" Rating by Barrington Research - MarketBeat
H.C. Wainwright reiterates Opko Health stock rating on Q1 results - Investing.com
OPKO Health Q1 2026 Earnings Call: Complete Transcript - Benzinga
OPKO Health Inc (OPK) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing ... By GuruFocus - Investing.com Canada
OPKO Health Q1 2026 Earnings Call Transcript - MarketBeat
OPKO Health Q1 Earnings Call Highlights - MarketBeat
OPK: Clinical pipeline advances and operational improvements drive improved Q1 2026 results - TradingView
1.19%
0.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):